Skip to content

News

5

November 5, 2020

In Publication and DataPosted November 5, 2020

SITC 2020 Presentation

Categories

Latest News (5)
Publication and Data (4)

Search for:

Recent Posts

Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
Tallac SITC 2021 Presentation
Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer
Tallac AACR 2021 Presentation

Archives

July 2022
May 2022
October 2021
April 2021
March 2021
December 2020
November 2020

(650) 866-1966

866 Malcolm Road Suite 100, Burlingame, CA 94010

Linkedin-in Envelope

Copyright © 2020-2022 Tallac Therapeutics, Inc. All Rights Reserved.